ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

Malcolm A Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.